{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T16:01:05Z","timestamp":1773504065652,"version":"3.50.1"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T00:00:00Z","timestamp":1602633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,14]],"date-time":"2020-10-14T00:00:00Z","timestamp":1602633600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Med Case Reports"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>The symptoms of drug-induced hepatic injury are manifold; however, the presence of ascites indicates a severe disease condition. The rapid accumulation of ascites is distressing and requires palliative treatment. Because many cases are addressed by repeated large-volume paracentesis, often resulting in impairment due to protein and electrolyte loss, a different approach is required.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Case presentation<\/jats:title>\n<jats:p>A 61-year-old Japanese man on maintenance dialysis was admitted to our hospital with acute liver injury. Our patient was diagnosed as having drug-induced liver injury due to warfarin or diltiazem, which started immediately after coronary artery bypass grafting 7\u2009months previously. One month after admission, our patient\u2019s hepatic encephalopathy remained grade 1 and his prothrombin time international normalized ratio was maintained at &lt;\u20091.5. However, the liver was markedly atrophied with massive ascites. Although liver transplantation was desired, he was considered unfit for transplantation because of his renal and cardiac complications. Therefore, we devised a strategy to manage the massive ascites with cell-free concentrated ascites reinfusion therapy while awaiting liver regeneration. At first, cell-free concentrated ascites reinfusion therapy was required frequently because ascites accumulated rapidly. But the fluid retention interval was gradually extended as intended, and cell-free concentrated ascites reinfusion therapy was withdrawn after 8\u2009months. During that time, the size of his liver increased from 1419\u2009cm<jats:sup>3<\/jats:sup> to 1587\u2009cm<jats:sup>3<\/jats:sup> on computed tomography.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Cell-free concentrated ascites reinfusion therapy is an apheresis therapy in which ascites are collected aseptically by paracentesis, concentrated, and then reinfused intravenously. This treatment has the advantage of preserving nutrition by reusing the fluid. Previously, cell-free concentrated ascites reinfusion therapy was used only for the management of ascites in patients with cirrhosis or carcinomatous peritonitis. This case suggests that palliation and maintenance of nutritional status with cell-free concentrated ascites reinfusion therapy may be useful as an adjunct to liver regeneration in drug-induced hepatic injury.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s13256-020-02507-5","type":"journal-article","created":{"date-parts":[[2020,10,13]],"date-time":"2020-10-13T23:03:48Z","timestamp":1602630228000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Ascites management by cell-free concentrated ascites reinfusion therapy during recovery from drug-induced acute liver injury: a case report"],"prefix":"10.1186","volume":"14","author":[{"given":"Koya","family":"Yasuda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mea","family":"Asou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiko","family":"Asakawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0854-4064","authenticated-orcid":false,"given":"Makoto","family":"Araki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,10,14]]},"reference":[{"key":"2507_CR1","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1056\/NEJMra1816149","volume":"381","author":"JH Hoofnagle","year":"2019","unstructured":"Hoofnagle JH, Bjornsson ES. Drug-induced liver injury - types and phenotypes. N Engl J Med. 2019;381:264\u201373.","journal-title":"N Engl J Med"},{"key":"2507_CR2","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1053\/j.gastro.2015.03.006","volume":"148","author":"N Chalasani","year":"2015","unstructured":"Chalasani N, Bonkovsky HL, Fontana R, et al. Features and outcomes of 899 patients with drug-induced liver injury: the DILIN prospective study. Gastroenterology. 2015;148:1340\u201352. e1347.","journal-title":"Gastroenterology"},{"key":"2507_CR3","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1007\/s13730-014-0109-2","volume":"3","author":"K Ito","year":"2014","unstructured":"Ito K, Ueda Y, Miyazawa H, et al. Acute severe liver dysfunction induced by febuxostat in a patient undergoing hemodialysis. CEN Case Rep. 2014;3:158\u201361.","journal-title":"CEN Case Rep"},{"key":"2507_CR4","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1002\/hep.23577","volume":"51","author":"DC Rockey","year":"2010","unstructured":"Rockey DC, Seeff LB, Rochon J, et al. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology. 2010;51:2117\u201326.","journal-title":"Hepatology"},{"key":"2507_CR5","first-page":"492","volume":"22","author":"O Parkash","year":"2012","unstructured":"Parkash O, Mumtaz K, Hamid S, et al. MELD score: utility and comparison with King's College criteria in non-acetaminophen acute liver failure. J Coll Physicians Surg Pak. 2012;22:492\u20136.","journal-title":"J Coll Physicians Surg Pak"},{"key":"2507_CR6","doi-asserted-by":"publisher","first-page":"e698","DOI":"10.1161\/CIRCULATIONAHA.105.603100","volume":"113","author":"N Arora","year":"2006","unstructured":"Arora N, Goldhaber SZ. Anticoagulants and transaminase elevation. Circulation. 2006;113:e698\u2013702.","journal-title":"Circulation"},{"key":"2507_CR7","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.jhep.2004.03.010","volume":"41","author":"CC Schimanski","year":"2004","unstructured":"Schimanski CC, Burg J, Mohler M, et al. Phenprocoumon-induced liver disease ranges from mild acute hepatitis to (sub-) acute liver failure. J Hepatol. 2004;41:67\u201374.","journal-title":"J Hepatol"},{"key":"2507_CR8","volume-title":"LiverTox: clinical and research information on drug-induced liver injury","author":"Warfarin","year":"2012","unstructured":"Warfarin. LiverTox: clinical and research information on drug-induced liver injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012."},{"key":"2507_CR9","volume-title":"LiverTox: clinical and research information on drug-induced liver injury","author":"Diltiazem","year":"2012","unstructured":"Diltiazem. LiverTox: clinical and research information on drug-induced liver injury. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012."},{"key":"2507_CR10","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.4254\/wjh.v8.i28.1182","volume":"8","author":"A Annamalai","year":"2016","unstructured":"Annamalai A, Wisdom L, Herada M, et al. Management of refractory ascites in cirrhosis: Are we out of date? World J Hepatol. 2016;8:1182\u201393.","journal-title":"World J Hepatol"},{"key":"2507_CR11","doi-asserted-by":"publisher","first-page":"215","DOI":"10.7326\/0003-4819-117-3-215","volume":"117","author":"BA Runyon","year":"1992","unstructured":"Runyon BA, Montano AA, Akriviadis EA, et al. The serum-ascites albumin gradient is superior to the exudate-transudate concept in the differential diagnosis of ascites. Ann Intern Med. 1992;117:215\u201320.","journal-title":"Ann Intern Med"},{"key":"2507_CR12","doi-asserted-by":"crossref","unstructured":"Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for liver cirrhosis: Ascites and related complications.Clin Mol Hepatol. 2018;24:230\u201377.","DOI":"10.3350\/cmh.2018.1005"},{"key":"2507_CR13","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1111\/aor.12933","volume":"41","author":"Y Yamada","year":"2017","unstructured":"Yamada Y, Harada M, Yamaguchi A, et al. Technical performance and clinical effectiveness of drop type with adjustable concentrator-cell free and concentrated ascites reinfusion therapy. Artif Organs. 2017;41:1135\u201344.","journal-title":"Artif Organs"},{"key":"2507_CR14","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s10147-011-0199-1","volume":"16","author":"K Matsusaki","year":"2011","unstructured":"Matsusaki K, Ohta K, Yoshizawa A, et al. Novel cell-free and concentrated ascites reinfusion therapy (KM-CART) for refractory ascites associated with cancerous peritonitis: its effect and future perspectives. Int J Clin Oncol. 2011;16:395\u2013400.","journal-title":"Int J Clin Oncol"},{"key":"2507_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0177303","volume":"12","author":"N Hanafusa","year":"2017","unstructured":"Hanafusa N, Isoai A, Ishihara T, et al. Safety and efficacy of cell-free and concentrated ascites reinfusion therapy (CART) in refractory ascites: post-marketing surveillance results. PLoS One. 2017;12:e0177303.","journal-title":"PLoS One"}],"container-title":["Journal of Medical Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-020-02507-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13256-020-02507-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13256-020-02507-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,14]],"date-time":"2021-10-14T00:20:54Z","timestamp":1634170854000},"score":1,"resource":{"primary":{"URL":"https:\/\/jmedicalcasereports.biomedcentral.com\/articles\/10.1186\/s13256-020-02507-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,14]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2507"],"URL":"https:\/\/doi.org\/10.1186\/s13256-020-02507-5","relation":{},"ISSN":["1752-1947"],"issn-type":[{"value":"1752-1947","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,14]]},"assertion":[{"value":"18 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"192"}}